- Home
- SYBT vs NRIX Comparison
SYBT vs NRIX Comparison
Compare SYBT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SYBT | NRIX |
|---|---|---|
| Founded | 1904 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.6B |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SYBT | NRIX |
|---|---|---|
| Price | $65.13 | $15.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $79.00 | $30.58 |
| AVG Volume (30 Days) | 159.6K | ★ 862.2K |
| Earning Date | 04-22-2026 | 04-10-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | $23,406,000.00 | ★ $76,987,000.00 |
| Revenue This Year | $16.83 | N/A |
| Revenue Next Year | $8.40 | $26.32 |
| P/E Ratio | $13.56 | ★ N/A |
| Revenue Growth | 3.37 | ★ 99.31 |
| 52 Week Low | $60.75 | $8.18 |
| 52 Week High | $83.83 | $22.50 |
Technical Indicators
Market Signals| Indicator | SYBT | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.19 | 50.50 |
| Support Level | $64.73 | $14.91 |
| Resistance Level | $71.41 | $16.47 |
| Average True Range (ATR) | 1.71 | 0.86 |
| MACD | 0.30 | 0.07 |
| Stochastic Oscillator | 82.26 | 72.60 |
Price Performance
Historical ComparisonAbout SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.